Meeting at the crossroads: Common mechanisms in Fragile X and Down syndrome

Trends in Neurosciences

Volumn 36, Issue 12, 2013, Pages 685-694

  Chang, Karen T ^a   Ro, Hyunah ^b   Wang, Wei ^b   Min, Kyung Tai ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Ulsan National Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CELL ADHESION MOLECULE; COFILIN; DICER; DOWN SYNDROME CELL ADHESION MOLECULE; DOWN SYNDROME CRITICAL REGION 1 PROTEIN; FRAGILE X MENTAL RETARDATION PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; METABOTROPIC RECEPTOR; MICRORNA; MICRORNA 125; MICRORNA 125B; MICRORNA 132; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; POSTSYNAPTIC DENSITY PROTEIN 95; REGULATOR PROTEIN; RNA INDUCED SILENCING COMPLEX; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ACTIN FILAMENT; CELL SIZE; CELL STRUCTURE; CHROMOSOME 21; DENDRITIC SPINE; DEPOLYMERIZATION; DNA METHYLATION; DOWN SYNDROME; FRAGILE X SYNDROME; GENE FUNCTION; GENE LOCUS; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; HOMEOSTASIS; HUMAN; INTELLECTUAL IMPAIRMENT; MISSENSE MUTATION; NERVE CELL DIFFERENTIATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN RNA BINDING; PROTEIN SYNTHESIS REGULATION; PSEUDOGENE; REVIEW; RNA TRANSLATION; SYNAPTIC EFFICACY; SYNAPTIC TRANSMISSION; TRANSCRIPTION TERMINATION; TRANSLATION REGULATION; TRINUCLEOTIDE REPEAT; UBIQUITINATION;

ANIMALS; DENDRITIC SPINES; DOWN SYNDROME; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSCLE PROTEINS;

EID: 84888876863     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2013.08.007     Document Type: Review

References (123)

1. Ji Y., et al. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients. Neuroscience 2003, 122:305-315.
2. Moolman D.L., et al. Dendrite and dendritic spine alterations in Alzheimer models. J. Neurocytol. 2004, 33:377-387.
3. Spires T.L., et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 2005, 25:7278-7287.
4. Zaja-Milatovic S., et al. Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology 2006, 66:1591-1593.
5. Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010, 120:131-143.
6. Barros C.S., et al. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4507-4512.
7. Hayashi-Takagi A., et al. Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nat. Neurosci. 2010, 13:327-332.
8. Kvajo M., et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7076-7081.
9. Zhou Z., et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006, 52:255-269.
10. Chao H.T., et al. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 2007, 56:58-65.
11. Bagni C., Greenough W.T. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat. Rev. Neurosci. 2005, 6:376-387.
12. Bassell G.J., Warren S.T. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008, 60:201-214.
13. Waung M.W., Huber K.M. Protein translation in synaptic plasticity: mGluR-LTD, fragile X. Curr. Opin. Neurobiol. 2009, 19:319-326.
14. Dierssen M., Ramakers G.J.A. Dendritic pathology in mental retardation: from molecular genetics to neurobiology. Genes Brain Behav. 2006, 5(Suppl. 2):48-60.
15. Belichenko P.V., et al. Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 2004, 480:281-298.
16. Belichenko N.P., et al. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J. Neurosci. 2009, 29:5938-5948.
17. Santoro M.R., et al. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu. Rev. Pathol. Mech. Dis. 2012, 7:219-245.
18. Weiler I.J., et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:5395-5400.
19. Irwin S.A., et al. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb. Cortex 2000, 10:1038-1044.
20. Patterson D. Molecular genetic analysis of Down syndrome. Hum. Genet. 2009, 126:195-214.
21. Antonarakis S.E., Epstein C.J. The challenge of Down syndrome. Trends Mol. Med. 2006, 12:473-479.
22. Rumble B., et al. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N. Engl. J. Med. 1989, 320:1446-1452.
23. Sturgeon X., Gardiner K.J. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm. Genome 2011, 22:261-271.
24. Korbel J.O., et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12031-12036.
25. Vacano G.N., et al. The use of mouse models for understanding the biology of down syndrome and aging. Curr. Gerontol. Geriatr. Res. 2012, 2012:717315.
26. Wang W., et al. DSCR1 interacts with FMRP and is required for spine morphogenesis and local protein synthesis. EMBO J. 2012, 31:3655-3666.
27. Bear M.F., et al. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377.
28. Penagarikano O., et al. The pathophysiology of fragile X syndrome. Annu. Rev. Genomics Hum. Genet. 2007, 8:109-129.
29. Schaeffer C., et al. The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J. 2001, 20:4803-4813.
30. Ramos A., et al. The structure of the N-terminal domain of the fragile X mental retardation protein: a platform for protein-protein interaction. Structure 2006, 14:21-31.
31. Lacoux C., et al. BC1-FMRP interaction is modulated by 2'-O-methylation: RNA-binding activity of the tudor domain and translational regulation at synapses. Nucleic Acids Res. 2012, 40:4086-4096.
32. Brown V., et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001, 107:477-487.
33. Darnell J.C., et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261.
34. Marin-Padilla M. Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. J. Comp. Neurol. 1976, 167:63-81.
35. Muddashetty R.S., et al. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling. Mol. Cell 2011, 42:673-688.
36. Niere F., et al. Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression. J. Neurosci. 2012, 32:5924-5936.
37. Rueda N., et al. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 2008, 433:22-27.
38. Napoli I., et al. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 2008, 134:1042-1054.
39. Westmark C.J., Malter J.S. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 2007, 5:e52.
40. Waung M.W., et al. Rapid translation of Arc/Arg3.1 selectively mediates mGluR-dependent LTD through persistent increases in AMPAR endocytosis rate. Neuron 2008, 59:84-97.
41. Park S., et al. Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuron 2008, 59:70-83.
42. Muddashetty R.S., et al. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J. Neurosci. 2007, 27:5338-5348.
43. Zalfa F., et al. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat. Neurosci. 2007, 10:578-587.
44. Huang F., et al. The mRNA for elongation factor 1alpha is localized in dendrites and translated in response to treatments that induce long-term depression. J. Neurosci. 2005, 25:7199-7209.
45. Bramham C.R., Wells D.G. Dendritic mRNA: transport, translation and function. Nat. Rev. Neurosci. 2007, 8:776-789.
46. Liao L., et al. Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15281-15286.
47. Darnell J.C., et al. Kissing complex RNAs mediate interaction between the fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev. 2005, 19:903-918.
48. Zang J.B., et al. A mouse model of the human fragile X syndrome I304N mutation. PLoS Genet. 2009, 5:e1000758.
49. Jin P., et al. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat. Neurosci. 2004, 7:113-117.
50. Plante I., et al. Dicer-derived microRNAs are utilized by the fragile X mental retardation protein for assembly on target RNAs. J. Biomed. Biotechnol. 2006, 2006:64347.
51. Cheever A., Ceman S. Phosphorylation of FMRP inhibits association with Dicer. RNA 2009, 15:362-366.
52. Edbauer D., et al. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 2010, 65:373-384.
53. Hoeffer C.A., et al. The Down syndrome critical region protein RCAN1 regulates long-term potentiation and memory via inhibition of phosphatase signaling. J. Neurosci. 2007, 27:13161-13172.
54. Chang K.T., et al. The Drosophila homolog of Down's syndrome critical region 1 gene regulates learning: implications for mental retardation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15794-15799.
55. Dierssen M., et al. Behavioral characterization of a mouse model overexpressing DSCR1/RCAN1. PLoS ONE 2011, 6:e17010.
56. Martin K.R., et al. Over-expression of RCAN1 causes Down syndrome-like hippocampal deficits that alter learning and memory. Hum. Mol. Genet. 2012, 21:3025-3041.
57. Davidovic L., et al. The fragile X mental retardation protein is a molecular adaptor between the neurospecific KIF3C kinesin and dendritic RNA granules. Hum. Mol. Genet. 2007, 16:3047-3058.
58. Dictenberg J.B., et al. A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev. Cell 2008, 14:926-939.
59. Kingsbury T.J., Cunningham K.W. A conserved family of calcineurin regulators. Genes Dev. 2000, 14:1595-1604.
60. Arron J.R., et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006, 441:595-600.
61. Osterweil E.K., et al. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 2010, 30:15616-15627.
62. Liu Q., et al. Interaction between TAK1-TAB1-TAB2 and RCAN1-calcineurin defines a signalling nodal control point. Nat. Cell Biol. 2009, 11:154-161.
63. Hilioti Z., et al. GSK-3 kinases enhance calcineurin signaling by phosphorylation of RCNs. Genes Dev. 2004, 18:35-47.
64. Ma L., et al. p38α MAP kinase phosphorylates RCAN1 and regulates its interaction with calcineurin. Sci. China Life Sci. 2012, 55:559-566.
65. Jung M.S., et al. Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation. J. Biol. Chem. 2011, 286:40401-40412.
66. Takashima S., et al. Dendritic and histochemical development and ageing in patients with Down's syndrome. J. Intellect. Disabil. Res. 1994, 38:265-273.
67. Ferrer I., Gullotta F. Down's syndrome and Alzheimer's disease: dendritic spine counts in the hippocampus. Acta. Neuropathol. 1990, 79:680-685.
68. Barbosa A.C., et al. MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9391-9396.
69. Flavell S.W., et al. Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. Neuron 2008, 60:1022-1038.
70. Pulipparacharuvil S., et al. Cocaine regulates MEF2 to control synaptic and behavioral plasticity. Neuron 2008, 59:621-633.
71. Pfeiffer B.E., et al. Fragile X mental retardation protein is required for synapse elimination by the activity-dependent transcription factor MEF2. Neuron 2010, 66:191-197.
72. Tsai N-P., et al. Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95. Cell 2012, 151:1581-1594.
73. Colledge M., et al. Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron 2003, 40:595-607.
74. Shin S-Y., et al. A hidden incoherent switch regulates RCAN1 in the calcineurin-NFAT signaling network. J. Cell Sci. 2011, 124:82-90.
75. Chin E.R., et al. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev. 1998, 12:2499-2509.
76. Putt M.E., et al. Evidence for coregulation of myocardial gene expression by MEF2 and NFAT in human heart failure. Circ. Cardiovasc. Genet. 2009, 2:212-219.
77. Hotulainen P., et al. Defining mechanisms of actin polymerization and depolymerization during dendritic spine morphogenesis. J. Cell Biol. 2009, 185:323-339.
78. Hotulainen P., Hoogenraad C.C. Actin in dendritic spines: connecting dynamics to function. J. Cell Biol. 2010, 189:619-629.
79. Cingolani L.A., Goda Y. Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy. Nat. Rev. Neurosci. 2008, 9:344-356.
80. Zhou Q., et al. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 2004, 44:749-757.
81. Castets M., et al. FMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts. Hum. Mol. Genet. 2005, 14:835-844.
82. Bramham C.R. Local protein synthesis, actin dynamics, and LTP consolidation. Curr. Opin. Neurobiol. 2008, 18:524-531.
83. Cajigas I.J., et al. Protein homeostasis and synaptic plasticity. EMBO J. 2010, 29:2746-2752.
84. Nelson D.L., et al. The unstable repeats - three evolving faces of neurological disease. Neuron 2013, 77:825-843.
85. Nosyreva E.D., Huber K.M. Developmental switch in synaptic mechanisms of hippocampal metabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 2005, 25:2992-3001.
86. Hou L., et al. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 2006, 51:441-454.
87. Ronesi J.A., Huber K.M. Metabotropic glutamate receptors and fragile X mental retardation protein: partners in translational regulation at the synapse. Sci. Signal. 2008, 1:pe6.
88. Shang Y., et al. Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice. J. Neurochem. 2009, 111:635-646.
89. Nosyreva E.D., Huber K.M. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J. Neurophysiol. 2006, 95:3291-3295.
90. Wang H., et al. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 2008, 59:634-647.
91. Siarey R.J., et al. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down syndrome. Neurophamcology 1997, 36:1549-1554.
92. Huber K.M., et al. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7746-7750.
93. Heulens I., et al. Craniofacial characteristics of fragile X syndrome in mouse and man. Eur. J. Hum. Genet. 2012, 21:816-823.
94. B receptors with arbaclofen. Sci. Transl. Med. 2012, 4:152ra128.
95. Bittner T., et al. Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J. Neurosci. 2009, 29:10405-10409.
96. Lee K.J., et al. Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines. Neuroscience 2010, 169:344-356.
97. Yamakawa K., et al. DSCAM: a novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system. Hum. Mol. Genet. 1998, 7:227-237.
98. Hattori D., et al. Dscam-mediated cell recognition regulates neural circuit formation. Annu. Rev. Cell Dev. Biol. 2008, 24:597-620.
99. Cvetkovska V., et al. Overexpression of Down syndrome cell adhesion molecule impairs precise synaptic targeting. Nat. Neurosci. 2013, 16:677-682.
100. Kim J.H., et al. Dscam expression levels determine presynaptic arbor sizes in Drosophila sensory neurons. Neuron 2013, 78:827-838.
101. Kurt M.A., et al. Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Res. 2000, 858:191-197.
102. Fotaki V., et al. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol. Cell. Biol. 2002, 22:6636-6647.
103. Hammerle B., et al. Mnb/Dyrk1A is transiently expressed and asymmetrically segregated in neural progenitor cells at the transition to neurogenic divisions. Dev. Biol. 2002, 246:259-273.
104. Yabut O., et al. Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells. J. Neurosci. 2010, 30:4004-4014.
105. Arque G., et al. Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice. Neurobiol. Dis. 2009, 36:312-319.
106. Ahn K.J., et al. DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol. Dis. 2006, 22:463-472.
107. Tejedor F., et al. minibrain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron 1995, 14:287-301.
108. Altafaj X., et al. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 2001, 10:1915-1923.
109. +/- mouse. Neurobiol. Dis. 2005, 20:115-122.
110. Martinez de Lagran M., et al. Dyrk1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons. Cereb. Cortex 2012, 22:2867-2877.
111. Chang K.T., Min K-T. Upregulation of three Drosophila homologs of human chromosome 21 genes alters synaptic function: implications for Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17117-17122.
112. Marin-Padilla M. Structural abnormalities of the cerebral cortex in human chromosomal aberrations: a Golgi study. Brain Res. 1972, 44:625-629.
113. Kurt M.A., et al. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res. 2004, 1022:101-109.
114. Wisniewski K.E., et al. The Fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. Am. J. Med. Genet. 1991, 38:476-480.
115. McKinney B.C., et al. Dendritic spine abnormalities in the occipital cortex of C57BL/6 Fmr1 knockout mice. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2005, 136B:98-102.
116. Galvez R., Greenough W.T. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am. J. Med. Genet. A 2005, 135:155-160.
117. Jung C.K., Herms J. Role of APP for dendritic spine formation and stability. Exp. Brain Res. 2012, 217:463-470.
118. Maynard K.R., Stein E. DSCAM contributes to dendrite arborization and spine formation in the developing cerebral cortex. J. Neurosci. 2012, 32:16637-16650.
119. Thomas S., et al. Intersectin regulates dendritic spine development and somatodendritic endocytosis but not synaptic vesicle recycling in hippocampal neurons. J. Biol. Chem. 2009, 284:12410-12419.
120. Fuentes J.J., et al. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum. Mol. Genet. 2000, 9:1681-1690.
121. Ermak G., et al. RCAN1 (DSCR1 or Adapt78) stimulates expression of GSK-3beta. FEBS J. 2006, 273:2100-2109.
122. Davies K.J.A., et al. Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin. FASEB J. 2007, 21:3023-3028.
123. Ascano M., et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 2012, 492:382-386.